- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01481831
Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting (ESPNV)
A Multi-center, Stratified Randomized, Controlled Study to Evaluate the Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in China
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Group I (Highly Emetogenic Chemotherapy): Patients that accepted chemotherapy including Cisplatin≥50mg/m2, Carmustine>250mg/m2, Cyclophosphamide>1500mg/m2, Dacarbazine>60mg/m2, Doxorubicin>60mg/m2, Epirubicin>90mg/m2, IFO≥10g/m2 or AC program.
Group II (Moderately Emetogenic Chemotherapy): Patients that accepted chemotherapy including any dose of Carboplatin, Daunorubicin, Oaliplatin, Irinotecan, or Doxorubicin<60mg/m2(not include liposomal doxorubicin), Epirubicin≤90mg/m2, Carmustine≤250mg/m2, Methotrexate≥250mg/m2, Cyclophosphamide≤1500mg/m2, Arabinoside>200mg/m2, IFO<10g/m2, Cisplatin≥50mg/m2.
Total subjects: 1000, single dose of palonosetron group of 500 patients, repeated doses of palonosetron group of 500 patients. According to the study subjects receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy, subjects are stratified randomize.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Anhui
-
Hefei, Anhui, Porcelana
- Anhui Provincial Hospital
-
-
Beijing
-
Beijing, Beijing, Porcelana
- Chinese Academy of Medical Sciences Cancer Hospital
-
Beijing, Beijing, Porcelana
- Chinese PLA 301 Hospital
-
Beijing, Beijing, Porcelana
- Chinese PLA 307 Hospital
-
Beijing, Beijing, Porcelana
- Chinese PLA Navy General Hospital
-
-
Fujian
-
Fuzhou, Fujian, Porcelana
- Fuzhou General hospital of Nanjing Military Command
-
-
Guangxi
-
Nanning, Guangxi, Porcelana
- Guangxi Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, Porcelana
- The Second Xiangya Hospital of Central South University
-
-
Jiangsu
-
Changzhou, Jiangsu, Porcelana
- The First People's Hospital of Changzhou
-
Nanjing, Jiangsu, Porcelana
- Nanjing General Hospital of Nanjing Military Command
-
Suzhou, Jiangsu, Porcelana
- The First Affiliated Hospital of Soochow University
-
Wuxi, Jiangsu, Porcelana
- The Fourth People's Hospital of Wuxi
-
-
Shandong
-
Jinan, Shandong, Porcelana
- Shandong Provincial Hospital
-
Jinan, Shandong, Porcelana
- Shandong Cancer Hospital
-
Qingdao, Shandong, Porcelana
- The Affiliated Hospital of Medical College Qingdao University
-
-
Shanghai
-
Shanghai, Shanghai, Porcelana
- Shanghai Changzheng Hospital
-
Shanghai, Shanghai, Porcelana
- Shanghai Xinhua hospital
-
-
Shanxi
-
Xian, Shanxi, Porcelana
- Tangdu Hospital of Fourth Military Medical University
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients candidates to a chemotherapy treatment, with histologically or cytologically confirmed malignant disease;
- The concrete chemotherapy plan does not limited, group I (Highly Emetogenic Chemotherapy), group II (Moderately Emetogenic Chemotherapy);
- Male or female aged 18-75 years, ECOG≤2, estimates survival time≥3 months;
- WBC≥3.0×109/L, ANC≥1.5×109/L, PLT≥80×109/L, total bilirubin≤1.5×ULN(Normal value upper limit), AST and ALT≤2.5×ULN(With transferability liver cancer≤5×ULN), Cr and BUN≤1.5×ULN, electrolyte and electrocardiogram are normal, conforms to the chemotherapy adaptation;
- Patients have been apart from the previous chemotherapy to finish above 2 weeks (including 2 weeks);
- Patients that voluntarily sign the consent form.
Exclusion Criteria:
- Pregnancy, or patients during breast feeding;
- Patients have accepted any radiotherapy during the experimental period;
- Gastric outlet or intestinal obstruction;
- Patients have serious heart diseases, liver kidney diseases, or metabolism function disorder;
- Patients have epilepsy, or have been used psychotropic drug and calm drug;
- Received any drugs with potential anti-emetic efficacy, or experienced any vomiting, nausea or retching in the 24 hours prior to chemotherapy;
- Patients with transferability brain tumor, have vomiting caused by skull high pressure, or can not speak sickness situation and adverse reactions by self;
- Patients have known hypersensitivity to 5-HT3 antagonists;
- Patients have chemotherapy contraindications;
- Patients are participating, or have participated in other Clinical studies of new drugs within 2 weeks.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: H PALO day 1
Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
|
0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
|
Experimental: H PALO day 1,3,5
Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
|
0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
|
Comparador activo: M PALO day 1
Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
|
0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
|
Experimental: M PALO day 1,3,5
Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
|
0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Complete Response rate
Periodo de tiempo: 2-7 days
|
defined as no emetic episode and no use of rescue medication
|
2-7 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Complete Response rate
Periodo de tiempo: 0-24 hours, 0-7 days
|
defined as no emetic episode and no use of rescue medication
|
0-24 hours, 0-7 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Signos y Síntomas Digestivos
- Náuseas
- Vómitos
- Efectos fisiológicos de las drogas
- Agentes neurotransmisores
- Mecanismos moleculares de acción farmacológica
- Agentes Autonómicos
- Agentes del sistema nervioso periférico
- Antieméticos
- Agentes Gastrointestinales
- Agentes de serotonina
- Antagonistas de serotonina
- Antagonistas del receptor de serotonina 5-HT3
- Palonosetrón
Otros números de identificación del estudio
- zhiruo
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Palonosetron Hydrochloride
-
Xiamen LP Pharmaceutical Co., LtdReclutamientoNáuseas y vómitos inducidos por quimioterapiaEstados Unidos
-
Consorzio OncotechTerminadoNáuseas y vómitos inducidos por quimioterapia
-
Sichuan Cancer Hospital and Research InstituteAún no reclutandoCarcinoma de células escamosas de cabeza y cuello (HNSCC)Porcelana
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); Eisai Inc.Terminado
-
Yonsei UniversityTerminado
-
Merck Sharp & Dohme LLCTerminadoNeoplasias | Náuseas | Vómitos
-
Yeungnam University College of MedicineTerminadoNáuseas postoperatorias | Vómitos PostoperatoriosCorea, república de
-
NYU Langone HealthEisai Inc.Terminado
-
Kangdong Sacred Heart HospitalAstellas Pharma Korea, Inc.; The Catholic University of KoreaTerminadoCáncer | TumoresCorea, república de
-
Azienda Ospedaliera di PerugiaDesconocido